非酒精性脂肪性肝病(NAFLD)合并2型糖尿病患者肝病严重程度的无创评估
该个体患者数据荟萃分析纳入1780例经活检证实的NAFLD合并2型糖尿病患者,评估FIB-4、NFS、APRI、振动控制瞬时弹性成像肝硬度测量(LSM)和AGILE 3+对进展期纤维化、NASH和纤维化性NASH的诊断准确性。LSM和AGILE 3+对进展期纤维化和纤维化性NASH的诊断准确性优于NFS和FIB-4,血清学与LSM联合可减少40%-60%的必要LSM检查。
要点
- 在NAFLD合并2型糖尿病患者中,LSM和AGILE 3+对进展期纤维化的诊断准确性优于NFS和FIB-4。
- 血清学指标与LSM序贯联合可使进展期纤维化所需的LSM检查减少40%-60%。
- 所有无创评分对NASH的诊断均不理想,对纤维化性NASH的诊断准确性尚可接受。
核心结论
- 在NAFLD合并2型糖尿病患者中,LSM和AGILE 3+单独应用或在资源有限时于FIB-4或NFS之后序贯联合应用,对进展期纤维化具有相似的良好诊断准确性,对纤维化性NASH具有可接受的诊断准确性。
研究设计与样本
- 本研究为个体患者数据荟萃分析,纳入1780例经活检证实的NAFLD合并2型糖尿病患者。
- 评估指标包括FIB-4、NAFLD纤维化评分(NFS)、天冬氨酸氨基转移酶与血小板比值指数(APRI)、振动控制瞬时弹性成像肝硬度测量(LSM)和AGILE 3+。
- 目标条件为进展期纤维化、NASH和纤维化性NASH(NASH合并F2-F4纤维化)。
- 诊断性能通过受试者工作特征曲线下面积和决策曲线分析评估,并与2278例不合并2型糖尿病的NAFLD患者进行比较。
主要发现
- 在NAFLD合并2型糖尿病患者中,LSM和AGILE 3+对进展期纤维化的诊断准确性优于NFS和FIB-4(受试者工作特征曲线下面积:LSM 0.82、AGILE 3+ 0.82、NFS 0.72、FIB-4 0.75、APRI 0.68;基于LSM的检测与简单血清学检测比较P < 0.001),不确定区域为12%-20%。
- 血清学检测与基于LSM的检测联合用于进展期纤维化,使必要的LSM检查减少40%-60%。
- 决策曲线分析显示,在漏诊进展期纤维化风险阈值为5%-10%时,所有评分对排除进展期纤维化均有适度的净获益。
- LSM和AGILE 3+对纤维化性NASH的诊断准确性优于NFS和FIB-4(受试者工作特征曲线下面积:LSM 0.79、AGILE 3+ 0.77、NFS 0.71、FIB-4 0.71;基于LSM的检测与简单血清学检测比较P < 0.001)。
- 所有无创评分对NASH的诊断均不理想。
关键数值与推荐
- 进展期纤维化:LSM曲线下面积0.82,AGILE 3+曲线下面积0.82,NFS曲线下面积0.72,FIB-4曲线下面积0.75,APRI曲线下面积0.68(基于LSM的检测与简单血清学检测比较P < 0.001)。
- 纤维化性NASH:LSM曲线下面积0.79,AGILE 3+曲线下面积0.77,NFS曲线下面积0.71,FIB-4曲线下面积0.71(基于LSM的检测与简单血清学检测比较P < 0.001)。
- 不确定区域为12%-20%。
- 血清学检测与基于LSM的检测联合使必要的LSM检查减少40%-60%。
- 决策曲线分析显示所有评分在漏诊进展期纤维化风险阈值5%-10%时均有适度的净获益。
临床怎么用
- 在NAFLD合并2型糖尿病患者中,可单独应用LSM或AGILE 3+评估进展期纤维化和纤维化性NASH。
- 在资源有限时,可于FIB-4或NFS之后序贯联合应用LSM或AGILE 3+,以减少必要的LSM检查。
- 所有无创评分对NASH的诊断均不理想。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: We evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in NAFLD patients with type 2 diabetes (T2D). METHODS AND RESULTS: This was an individual patient data meta-analysis of 1780 patients with biopsy-proven NAFLD and T2D. The index tests of interest were FIB-4, NAFLD Fibrosis Score (NFS), aspartate aminotransferase-to-platelet ratio index, liver stiffness measurement (LSM) by vibration-controlled transient elastography, and AGILE 3+. The target conditions were advanced fibrosis, NASH, and fibrotic NASH(NASH plus F2-F4 fibrosis). The diagnostic performance of noninvasive tests. individually or in sequential combination, was assessed by area under the receiver operating characteristic curve and by decision curve analysis. Comparison with 2278 NAFLD patients without T2D was also made. In NAFLD with T2D LSM and AGILE 3+ outperformed, both NFS and FIB-4 for advanced fibrosis (area under the receiver operating characteristic curve:LSM 0.82, AGILE 3+ 0.82, NFS 0.72, FIB-4 0.75, aspartate aminotransferase-to-platelet ratio index 0.68; p < 0.001 of LSM-based versus simple serum tests), with an uncertainty area of 12%-20%. The combination of serum-based with LSM-based tests for advanced fibrosis led to a reduction of 40%-60% in necessary LSM tests. Decision curve analysis showed that all scores had a modest net benefit for ruling out advanced fibrosis at the risk threshold of 5%-10% of missing advanced fibrosis. LSM and AGILE 3+ outperformed both NFS and FIB-4 for fibrotic NASH (area under the receiver operating characteristic curve:LSM 0.79, AGILE 3+ 0.77, NFS 0.71, FIB-4 0.71; p < 0.001 of LSM-based versus simple serum tests). All noninvasive scores were suboptimal for diagnosing NASH. CONCLUSIONS: LSM and AGILE 3+ individually or in low availability settings in sequential combination after FIB-4 or NFS have a similar good diagnostic accuracy for advanced fibrosis and an acceptable diagnostic accuracy for fibrotic NASH in NAFLD patients with T2D.
引用
- Pennisi G, Enea M, Falco V, et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology. 2023. PMID: 36924031. doi:10.1097/HEP.0000000000000351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。